Literature DB >> 16549972

Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment.

David J Moore1, Eliezer Masliah, Julie D Rippeth, Raul Gonzalez, Catherine L Carey, Mariana Cherner, Ronald J Ellis, Cristian L Achim, Thomas D Marcotte, Robert K Heaton, Igor Grant.   

Abstract

OBJECTIVE: To determine the association of markers of regional neurodegeneration (ND) at autopsy to degree of neurocognitive impairment in persons with HIV.
DESIGN: In a prospectively followed cohort of HIV-infected individuals we examined the relationship between antemortem neuropsychological (NP) abilities and postmortem neuropathological data.
METHODS: Twenty-seven HIV-infected individuals with both neuropsychological and neuropathological data were identified. Laser confocal scanning microscopy was used to determine the degree of ND based on: (1) microtubule-associated protein (MAP2; reflecting neuronal cell bodies and dendrites) and (2) synaptophysin (SYN; a measure of presynaptic terminals). A regional combined score, based on the distribution of percentage neuropil occupied by MAP2 and SYN and emphasizing severity of ND, was created for each brain region: midfrontal cortex, hippocampus, and putamen.
RESULTS: The regional combined scores from each brain region studied were better correlated with level of global NP impairment than measures of SYN and MAP2 individually. In a regression, hippocampal and putamen regional combined scores were independent predictors of degree of antemortem NP impairment (F(3,23) = 6.17; P < 0.01; R2 = 0.45). The correlations among regional ND measures demonstrated that ND is unevenly distributed across multiple brain regions.
CONCLUSIONS: As the anatomic distribution and temporal progression of neuropathologic changes appears to differ across individuals, it is important to consider both cortical and subcortical brain regions in studies of neuropathogenesis and treatment of HIV-related brain disease. Furthermore, combining information from several markers of neural injury provided the strongest association with degree of neurocognitive impairment during life.

Entities:  

Mesh:

Year:  2006        PMID: 16549972     DOI: 10.1097/01.aids.0000218552.69834.00

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  120 in total

1.  Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons.

Authors:  David J Moore; Miguel Arce; Suzanne Moseley; J Allen McCutchan; Jennifer Marquie-Beck; Donald R Franklin; Florin Vaida; Cristian L Achim; Justin McArthur; Susan Morgello; David M Simpson; Benjamin B Gelman; Ann C Collier; Christina M Marra; David B Clifford; Robert K Heaton; Igor Grant
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

2.  Effects of HIV and early life stress on amygdala morphometry and neurocognitive function.

Authors:  Uraina S Clark; Ronald A Cohen; Lawrence H Sweet; Assawin Gongvatana; Kathryn N Devlin; George N Hana; Michelle L Westbrook; Richard C Mulligan; Beth A Jerskey; Tara L White; Bradford Navia; Karen T Tashima
Journal:  J Int Neuropsychol Soc       Date:  2012-05-24       Impact factor: 2.892

3.  Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.

Authors:  Andrew J Levine; Susan Service; Eric N Miller; Sandra M Reynolds; Elyse J Singer; Paul Shapshak; Eileen M Martin; Ned Sacktor; James T Becker; Lisa P Jacobson; Paul Thompson; Nelson Freimer
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-24       Impact factor: 3.568

4.  ER-β mediates 17β-estradiol attenuation of HIV-1 Tat-induced apoptotic signaling.

Authors:  Sheila M Adams; Marina V Aksenova; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  Synapse       Date:  2010-11       Impact factor: 2.562

Review 5.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

6.  Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.

Authors:  Mariana Cherner; Chad Bousman; Ian Everall; Daniel Barron; Scott Letendre; Florin Vaida; J Hampton Atkinson; Robert Heaton; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2010-08-23       Impact factor: 2.892

7.  Changes in cognitive function in women with HIV infection and early life stress.

Authors:  Georgina Spies; Christine Fennema-Notestine; Mariana Cherner; Soraya Seedat
Journal:  AIDS Care       Date:  2016-07-11

8.  Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy.

Authors:  I Everall; F Vaida; N Khanlou; D Lazzaretto; C Achim; S Letendre; D Moore; R Ellis; M Cherner; B Gelman; S Morgello; E Singer; I Grant; E Masliah
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

Review 9.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

10.  Deficits in complex motor functions, despite no evidence of procedural learning deficits, among HIV+ individuals with history of substance dependence.

Authors:  Raul Gonzalez; Joanna Jacobus; Anup K Amatya; Phillip J Quartana; Jasmin Vassileva; Eileen M Martin
Journal:  Neuropsychology       Date:  2008-11       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.